Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUBVENITE vs KEPPRA XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Treatment of Parkinson's disease as monotherapy or adjunct to levodopa,Off-label: treatment of major depressive disorder (limited evidence)
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
Rasagiline is primarily metabolized by CYP1A2 to its major metabolite, 1-(R)-aminoindan. Minor pathways involve CYP2D6 and conjugation.
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Approximately 95% bound to plasma proteins, primarily albumin.
<10%; binding to albumin (not extensive).
Volume of distribution is approximately 3-7 L/kg, indicating extensive tissue distribution.
0.5–0.7 L/kg; suggests distribution into total body water.
Oral bioavailability is approximately 50-60%.
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
GFR 30-89 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose by 50%; increase dosing interval to every 12 hours. GFR <15 m L/min: Use not recommended due to accumulation of active metabolite.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
Child-Pugh A (mild): No adjustment. Child-Pugh B (moderate): Reduce starting dose by 50%; titrate cautiously. Child-Pugh C (severe): Avoid use.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
Approved for ages ≥6 years for breakthrough cancer pain: Dose based on prior opioid requirement; typical starting dose 2 mcg/kg sublingually; titrate by 2 mcg/kg as needed; maximum single dose 10 mcg/kg. Maximum 4 doses per day.
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
Use with caution; start at lowest available dose (2 mg sublingually). Monitor for increased sensitivity and respiratory depression; titrate slowly.
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
No FDA black box warning.
No FDA black box warning.
Hypertensive crisis with tyramine-rich foods, beverages, or drugs (e.g., sympathomimetics, other MAOIs),Serotonin syndrome when used with serotonergic drugs,May cause hallucinations, confusion, or impulse control disorders,May exacerbate dyskinesia when used with levodopa,Caution in patients with hepatic impairment
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
Concurrent use of other MAOIs (including linezolid or IV methylene blue),Concurrent use of sympathomimetic amines (e.g., amphetamines, cold products),Concurrent use of pethidine, SSRIs, SNRIs, tricyclic antidepressants, or St. John's wort,Pheochromocytoma,Severe hepatic impairment
Hypersensitivity to levetiracetam or any component of the formulation
No significant food interactions. Administer with food to reduce flushing and GI symptoms. Avoid alcohol as it may worsen flushing or liver enzyme elevation.
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies reported, but potential for neonatal adaptation syndrome at delivery.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
Excreted into breast milk; M/P ratio not determined. Due to risk of serious adverse reactions in breastfed infants, breastfeeding is not recommended during therapy.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
No formal studies; due to increased plasma volume and renal clearance in pregnancy, therapeutic effect may decrease. Consider monitoring drug levels or dose adjustment based on clinical response, but no established dosing schedule.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
Subvenite is a brand of dimethyl fumarate, used for relapsing forms of multiple sclerosis. Titrate starting dose to minimize flushing and GI adverse effects. Administer with food to reduce flushing. Monitor absolute lymphocyte count (ALC) regularly due to risk of lymphopenia. Consider PML risk with prolonged lymphopenia. Discontinue if ALC < 0.5x10^9/L for >6 months. Non-enteric coated aspirin 325 mg may reduce flushing severity when taken 30 minutes prior to dose.
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Take Subvenite exactly as prescribed, with or without food. Swallow capsules whole; do not crush or chew.,Flushing and stomach upset are common, especially at start. Taking with food and using aspirin (if recommended) can help.,You may need blood tests to monitor white blood cell counts before and during treatment.,Report any signs of infection (fever, persistent cough, fatigue) or new neurological symptoms.,Do not stop or change dose without consulting your doctor.,Store capsules at room temperature away from moisture and heat.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUBVENITE vs KEPPRA XR, answered by our medical review team.
SUBVENITE is a Antiepileptic that works by SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.. KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUBVENITE and KEPPRA XR depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUBVENITE is: Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.. The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUBVENITE and KEPPRA XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUBVENITE is classified as Category C. First trimester: Sufficient evidence of teratogenicity in animal studies; human data limited but risk cannot be excluded. Second and third trimesters: No specific fetal anomalies r. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.